体内研究 (In Vivo) |
IGN-2098 (10-30 mg/kg;口服;每日 2 次;连续 14 天) 可剂量依赖性地促进大鼠乙酸诱导胃溃疡的愈合,其中 10 mg/kg 和 30 mg/kg 剂量的愈合率分别达到 49.6%和 52.7%,且与对照组相比能显著降低溃疡边缘隆起程度。 IGN-2098 (1-60 mg/kg;口服、皮下注射、皮内注射、腹腔注射;单次给药) 可通过多种途径强效抑制幽门结扎大鼠的基础胃酸分泌,其中皮下注射的效力最高 (胃酸分泌抑制的 ED50 = 0.7 mg/kg)。 IGN-2098 (0.1-30 mg/kg; 皮下注射; 单次给药) 可强效抑制急性瘘管大鼠中组胺刺激的胃酸分泌,其 ED50 为 0.2 mg/kg。 IGN-2098 (0.3-30 mg/kg;皮下注射;单次给药) 可强效抑制急性瘘管大鼠中 Carbachol (MS-U27390) 刺激的胃酸分泌,其 ED50 为 0.3 mg/kg。 IGN-2098 (1-30 mg/kg;皮下注射;单次给药) 可强效抑制急性瘘管大鼠中 Pentagastrin (MS-H98907) 刺激的胃酸分泌,其 ED50 为 0.1 mg/kg。 IGN-2098 (3-60 mg/kg;皮下注射;单次给药) 可抑制麻醉大鼠中 2-deoxy-D-glucose (MS-N96486) 刺激的胃酸分泌,其 ED50 为 42.7 mg/kg。 IGN-2098 (3-60 mg/kg;口服、皮下注射;单次给药) 可抑制大鼠幽门结扎诱导的胃溃疡,其 ED50 为 29.7 mg/kg。 IGN-2098 (1-60 mg/kg;口服;单次给药) 可抑制大鼠水浸应激诱导的胃黏膜损伤,其 ED50 为 8.4 mg/kg。 IGN-2098 (0.3-3 mg/kg;口服;单次给药) 可强效抑制组胺诱导的大鼠胃黏膜损伤,其 ED50 为 0.9 mg/kg。 IGN-2098 (3-30 mg/kg;口服;单次给药) 可抑制 Indomethacin (MS-W76510) 诱导的大鼠胃黏膜损伤,其 ED50 为 5.4 mg/kg。 IGN-2098 (1-30 mg/kg;口服;单次给药) 可强效抑制大鼠体内盐酸-Aspirin (MS-D43752) 诱导的胃黏膜损伤,其 ED50 为 1.4 mg/kg。 IGN-2098 (3-60 mg/kg;口服;单次给药) 可抑制大鼠由盐酸-乙醇诱导的胃黏膜损伤,其 ED50 为 17.0 mg/kg。
| Animal Model: |
Sprague-Dawley (male, 7 weeks old, gastric ulcer induced by 20% acetic acid injection) |
| Dosage: |
10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; twice daily; 14 days |
| Result: |
Reduced mean ulcer index to 6.4 mm2 and achieved a 49.6% healing ratio at 10 mg/kg, with a significant difference versus control. Reduced mean ulcer index to 6.0 mm2 and achieved a 52.7% healing ratio at 30 mg/kg, with a significant difference versus control. Significantly reduced prominent ulcer edges versus control at both 10 mg/kg and 30 mg/kg. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
1-60 mg/kg (p.o.); 0.3-30 mg/kg (s.c.); 1-30 mg/kg (i.d.); 1-30 mg/kg (i.p.) |
| Administration: |
p.o.; single dose (0.5, 3, or 9 hours before pylorus ligation); s.c.; single dose (0.5 hours before pylorus ligation); i.d.; single dose (immediately after pylorus ligation); i.p.; single dose (0.5 hours before pylorus ligation) |
| Result: |
Reduced gastric juice volume by 53.1% and acid output by 78.5% at 10 mg/kg p.o. 0.5 hours before ligation, with an ED50 of 4.3 mg/kg for acid output inhibition. Reduced acid output by 71.7% at 10 mg/kg p.o. 3 hours before ligation, and by 88.0% at 30 mg/kg p.o. 3 hours before ligation, with an ED50 of 5.0 mg/kg. Reduced acid output by 66.5% at 30 mg/kg p.o. 9 hours before ligation, and by 78.8% at 60 mg/kg p.o. 9 hours before ligation, with an ED50 of 16.9 mg/kg. Reduced acid output by 71.2% at 1 mg/kg s.c., with an ED50 of 0.7 mg/kg. Reduced acid output by 65.0% at 3 mg/kg i.d., with an ED50 of 1.1 mg/kg. Reduced acid output by 64.5% at 10 mg/kg i.p., with an ED50 of 3.6 mg/kg. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
0.1-30 mg/kg |
| Administration: |
s.c.; single dose (0.5 hours before first histamine administration) |
| Result: |
Reduced histamine-stimulated acid output by 30.3% at 0.1 mg/kg, 69.3% at 0.3 mg/kg, 73.5% at 1 mg/kg, 89.4% at 3 mg/kg, 92.0% at 10 mg/kg, and 97.5% at 30 mg/kg. Achieved an ED50 of 0.2 mg/kg for acid output inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
0.3-30 mg/kg |
| Administration: |
s.c.; single dose (0.5 hours before carbachol infusion) |
| Result: |
Reduced carbachol-stimulated acid output by 42.9% at 0.3 mg/kg, 65.5% at 1 mg/kg, 78.1% at 3 mg/kg, 85.6% at 10 mg/kg, and 80.8% at 30 mg/kg. Achieved an ED50 of 0.3 mg/kg for acid output inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
1-30 mg/kg |
| Administration: |
s.c.; single dose (0.5 hours before pentagastrin infusion) |
| Result: |
Reduced pentagastrin-stimulated acid output by 79.5% at 1 mg/kg, 52.7% at 3 mg/kg, 84.9% at 10 mg/kg, and 98.3% at 30 mg/kg. Achieved an ED50 of 0.1 mg/kg for acid output inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
3-60 mg/kg |
| Administration: |
s.c.; single dose (0.5 hours after stimulated secretion stabilized) |
| Result: |
Reduced 2-deoxy-D-glucose-stimulated acid output by 65.9% at 60 mg/kg. Achieved an ED50 of 42.7 mg/kg for acid output inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
3-60 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before ligation); s.c.; single dose (7 hours after ligation) |
| Result: |
Reduced ulcer coefficients by 55.9% at 30 mg/kg, and 61.8% at 60 mg/kg. Achieved an ED50 of 29.7 mg/kg for ulcer inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
1-60 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before stress exposure) |
| Result: |
Reduced lesion length by 43.1% at 3 mg/kg, 59.1% at 10 mg/kg, 55.8% at 30 mg/kg, and 84.0% at 60 mg/kg. Achieved an ED50 of 8.4 mg/kg for lesion inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
0.3-3 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before histamine administration) |
| Result: |
Reduced lesion area by 86.7% at 3 mg/kg. Achieved an ED50 of 0.9 mg/kg for lesion inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
3-30 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before indomethacin administration) |
| Result: |
Reduced lesion length by 52.2% at 10 mg/kg, and 91.8% at 30 mg/kg. Achieved an ED50 of 5.4 mg/kg for lesion inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
1-30 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before HCl-aspirin administration) |
| Result: |
Reduced lesion length by 78.1% at 3 mg/kg, 90.9% at 10 mg/kg, and 95.0% at 30 mg/kg. Achieved an ED50 of 1.4 mg/kg for lesion inhibition. |
| Animal Model: |
Sprague-Dawley (male, SPF, 220-270g) |
| Dosage: |
3-60 mg/kg |
| Administration: |
p.o.; single dose (30 minutes before HCl-ethanol administration) |
| Result: |
Reduced lesion length by 62.0% at 20 mg/kg, 77.3% at 30 mg/kg, and 94.1% at 60 mg/kg. Achieved an ED50 of 17.0 mg/kg for lesion inhibition. |
|